KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Total Liabilities (2016 - 2025)

Neogenomics (NEO) has disclosed Total Liabilities for 16 consecutive years, with $523.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 28.87% year-over-year to $523.3 million, compared with a TTM value of $523.3 million through Dec 2025, down 28.87%, and an annual FY2025 reading of $523.3 million, down 28.87% over the prior year.
  • Total Liabilities was $523.3 million for Q4 2025 at Neogenomics, down from $536.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $769.1 million in Q3 2021 and bottomed at $523.3 million in Q4 2025.
  • Average Total Liabilities over 5 years is $704.3 million, with a median of $735.2 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 186.39% in 2021, then decreased 28.87% in 2025.
  • Year by year, Total Liabilities stood at $761.5 million in 2021, then decreased by 2.56% to $742.0 million in 2022, then decreased by 0.31% to $739.7 million in 2023, then dropped by 0.54% to $735.7 million in 2024, then fell by 28.87% to $523.3 million in 2025.
  • Business Quant data shows Total Liabilities for NEO at $523.3 million in Q4 2025, $536.5 million in Q3 2025, and $539.9 million in Q2 2025.